Tetrasodium Ethylenediaminetetraacetic Acid for Locking Central Venous Access Devices: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Details

Files

Project Line:

Reference List

Project Sub Line:

Summary of Abstracts

Project Number:

RB1324-000

Question

What is the clinical effectiveness of 4% tetrasodium ethylenediaminetetraacetic acid (EDTA) for locking central venous access devices (CVAD)?
What is the cost-effectiveness of 4% tetrasodium EDTA for locking CVADs?
What are the evidence-based guidelines regarding the use of CVADs?

Key Message

One randomized controlled trial was identified regarding 4% tetrasodium ethylenediaminetetraacetic acid (EDTA) for locking central venous access devices (CVADs). In addition, one evidence-based guideline was identified regarding the use of CVADs. No relevant economic evaluations were identified regarding the cost-effectiveness of 4% tetrasodium EDTA for locking CVADs.

Files

Tetrasodium Ethylenediaminetetraacetic Acid for Locking Central Venous Access Devices: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Rapid Response April 9, 2019 View PDF

Last Updated : April 9, 2019